Published in Semin Oncol on October 01, 1997
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (1999) 1.74
Bilateral lymphocytic alveolitis: a common reaction after unilateral thoracic irradiation. Eur Respir J (1999) 1.68
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) Ann Oncol (1998) 1.60
Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun (2001) 1.60
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol (2006) 1.58
Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol (1994) 1.56
Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. J Natl Cancer Inst (2010) 1.55
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer (2012) 1.48
Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med (1990) 1.43
Radioimmune imaging of bone marrow in patients with suspected bone metastases from primary breast cancer. J Nucl Med (1990) 1.42
Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis. Cancer Invest (1992) 1.39
Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group. Ann Oncol (1994) 1.39
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res (2000) 1.30
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer (2011) 1.27
[Assessment of the reliability of clinical findings: the intraclass correlation coefficient]. Med Clin (Barc) (1998) 1.26
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol (2005) 1.21
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol (2010) 1.15
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat (2011) 1.15
Comparison of the results of first and second cataract eye surgery. Ophthalmology (1999) 1.12
Bromodomain factor 1 (Bdf1) protein interacts with histones. FEBS Lett (2001) 1.09
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol (2004) 1.06
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol (2003) 1.04
Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol (2004) 1.04
High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol (1996) 1.03
Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. J Chemother (2008) 1.02
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann Oncol (2014) 1.01
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol (2015) 0.97
Structural basis for chitin recognition by defense proteins: GlcNAc residues are bound in a multivalent fashion by extended binding sites in hevein domains. Chem Biol (2000) 0.97
Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer (2012) 0.95
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol (2007) 0.94
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol (2009) 0.94
Latent forms of transforming growth factor-beta (TGF beta) derived from bone cultures: identification of a naturally occurring 100-kDa complex with similarity to recombinant latent TGF beta. Mol Endocrinol (1991) 0.93
Cathodoluminescence evaluation of defect structure in hydrothermally grown ZnO:Sb nanorods. J Nanosci Nanotechnol (2011) 0.93
Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol (2010) 0.92
Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol (1994) 0.92
Carboplatin: an active drug in metastatic breast cancer. J Clin Oncol (1992) 0.91
Biliary tract infections caused by Haemophilus influenzae type b. Eur J Clin Microbiol (1983) 0.91
Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Br J Cancer (2003) 0.90
High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. Ann Oncol (1991) 0.90
The conformation of C-glycosyl compounds. Adv Carbohydr Chem Biochem (2000) 0.89
Epidermal growth factor in plasma and saliva of patients with active breast cancer and breast cancer patients in follow-up compared with healthy women. Breast Cancer Res Treat (1997) 0.89
Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol (2008) 0.89
Enamel pearls and cervical enamel projections on 2 maxillary molars with localized periodontal disease: case report and histologic study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2000) 0.89
Preoperative induction chemotherapy followed by concurrent chemoradiotherapy in advanced carcinoma of the oral cavity and oropharynx. Cancer (2000) 0.89
Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial. Am J Clin Oncol (1992) 0.88
cis-platinum/vinblastine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary. Gynecol Oncol (1990) 0.88
Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. Ann Oncol (2011) 0.88
Molecular characterization and clonal diversity of methicillin-susceptible Staphylococcus aureus in milk of cows with mastitis in Brazil. J Dairy Sci (2013) 0.88
Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. Semin Oncol (2000) 0.87
Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas. Breast Cancer Res Treat (1999) 0.87
Primary neuroendocrine small cell undifferentiated carcinoma of the parotid gland. Clin Transl Oncol (2008) 0.87
Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels. Ann Oncol (2008) 0.87
Pharmacogenomics and gemcitabine. Ann Oncol (2006) 0.87
Treatment of small cell lung cancer with a combination of VP16-213 and cyclophosphamide with cisplatin or radiotherapy. Cancer Chemother Pharmacol (1982) 0.86
Free and protein-bound carbohydrate structures. Curr Opin Struct Biol (1999) 0.86
Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Cancer Chemother Pharmacol (2012) 0.86
Germ cell tumours of the ovary. Clin Transl Oncol (2007) 0.86
Overexpression of copper-zinc superoxide dismutase in trisomy 21. Experientia (1996) 0.86
Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin (2004) 0.85
Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. European Organization for Research and Treatment of Cancer. Gynecol Oncol (2001) 0.85
It is not time to stop progesterone receptor testing in breast cancer. J Clin Oncol (2005) 0.85
[Intestinal parasitic infections in 4 child day-care centers located in San Miguel del Padrón municipality, Havana City, 1998]. Rev Cubana Med Trop (2005) 0.85
Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer. Int J Cancer (2000) 0.85
Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (1999) 0.85
Predictive value of P53, BCL-2, and BAX in advanced head and neck carcinoma. Am J Clin Oncol (2002) 0.84
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer (1993) 0.84
Phase I study of mitonafide in solid tumors. Invest New Drugs (1992) 0.84
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer (2006) 0.84
End-stage acute hepatic failure as clinical presentation of liver metastases from breast cancer. Tumori (1999) 0.84
Ovarian and extragonadal malignant germ-cell tumors in females: a single-institution experience with 43 patients. Ann Oncol (1994) 0.84
Allele-frequency determination of BsmI and FokI polymorphisms of the VDR gene by quantitative real-time PCR (QRT-PCR) in pooled genomic DNA samples. J Steroid Biochem Mol Biol (2004) 0.84
Structure of complex cell wall polysaccharides isolated from Trichoderma and Hypocrea species. Carbohydr Res (1997) 0.83
Asymmetric Pauson-Khand reactions using camphor-derived chelating thiols as chiral controllers. J Org Chem (2001) 0.83
Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study. Eur J Cancer (2000) 0.83
Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases. Cancer (1992) 0.83
Electrophoretic behavior and size distribution of the acidic polysaccharides produced by the bacteria Bradyrhizobium (Chamaecytisus) strain BGA-1 and Bradyrhizobium japonicum USDA 110. Electrophoresis (1998) 0.83
Breast cancer in the elderly. Postgrad Med J (1995) 0.83
Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Semin Oncol (1995) 0.82
Apoptosis in ductal carcinoma in situ of the breast. Breast J (2001) 0.82
Apoptosis loss and bcl-2 expression: key determinants of lymph node metastases in T1 breast cancer. Clin Cancer Res (1996) 0.82
The evaluation of agreement on continuous variables by the intraclass correlation coefficient. J Epidemiol Community Health (1997) 0.82